Alumis Inc. Completes Patient Enrollment for Phase 3 ONWARD Clinical Program Evaluating ESK-001 in Moderate-to-Severe Plaque Psoriasis

Alumis Inc. (ALMS) has completed patient enrollment in its Phase 3 ONWARD clinical program, encompassing over 1,700 patients across two trials, to evaluate ESK-001 as a treatment for moderate-to-severe plaque psoriasis; topline results are expected in early Q1 2026. ESK-001, a next-generation oral TYK2 inhibitor, is positioned to potentially offer a more convenient and effective treatment option compared to existing therapies, addressing a critical gap in the market. Alumis is also exploring a once-daily formulation and long-term outcomes, while insiders have been actively purchasing ALMS stock in recent months.

Analysis

Alumis Inc. (ALMS) has achieved a significant operational milestone by completing patient enrollment for its pivotal Phase 3 ONWARD clinical program for ESK-001, a novel oral TYK2 inhibitor targeting moderate-to-severe plaque psoriasis. The program involves over 1,700 patients across two trials, ONWARD1 and ONWARD2, with topline results anticipated in early Q1 2026. This development positions ESK-001 as a potential improvement over existing treatments, offering biologic-like efficacy with the convenience of an oral formulation, potentially addressing the unmet needs of patients who cycle through therapies due to inconvenience or diminishing effectiveness. The company is also progressing a once-daily formulation and a long-term extension trial (ONWARD3) to assess durability and safety. Notably, ALMS insiders have demonstrated confidence through 12 open market purchases totaling significant value over the past six months, with zero sales reported, including substantial buys from CEO Martin Babler, SRINIVAS AKKARAJU, and Foresite Capital entities. While the completion of enrollment is a positive step, the outcome of the Phase 3 trials remains a critical determinant of future success, and the company acknowledges risks associated with forward-looking statements, regulatory approval, and commercialization. The successful development of ESK-001, which is also being evaluated for systemic lupus erythematosus, could significantly alter Alumis' market position and growth trajectory.

Key Decisions for Investors

• Investors should view the completion of Phase 3 enrollment for ESK-001 as a key de-risking event, though the primary catalyst remains the topline data readout expected in early Q1 2026.
• The consistent and substantial insider buying activity over the past six months signals strong internal conviction in ESK-001's potential and the company's prospects, warranting close attention.
• Given the timeline to data and potential regulatory hurdles, positions in ALMS should be considered with a long-term horizon, acknowledging the binary risk typical of late-stage biopharmaceutical companies awaiting pivotal trial results.
• Monitor progress on the once-daily formulation of ESK-001 and developments in its Phase 2b trial for systemic lupus erythematosus, as these represent additional value drivers and market expansion opportunities.